Tag: riociguat Adempas

All

No Benefit for Idiopathic Interstitial Pneumonia-associated PH Patients Treated with Adempas

For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.

Positive Data for PAH Patients Treated with Riociguat
Bayer Enrolling Patients in Phase 4 PAH Trial of Riociguat
Bayer to Present Data on PAH Drugs at ATS 2017
EMA Halts Use of Riociguat for PH Associated Idiopathic Interstitial Pneumonia
Riociguat Safe, Effective for Treating CTEPH Long-term
Bayer Terminates Phase II Study of Riociguat for PH-associated Idiopathic Interstitial Pneumonias
Riociguat Provides Hope for Difficult-to-Treat PAH Patients

All

Novel Pulmonary Hypertension Drug Proves Safe, Effective

After a year of being treated with a novel drug, Riociguat, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), and those with persistent or recurrent pulmonary hypertension after an operation for the disease, showed sustained improvement.

Bayer’s Investigational Drug Shows Promise in PAH Treatment, Phase III Study Finds

Tag: riociguat Adempas

All

No Benefit for Idiopathic Interstitial Pneumonia-associated PH Patients Treated with Adempas

Positive Data for PAH Patients Treated with Riociguat

Bayer Enrolling Patients in Phase 4 PAH Trial of Riociguat

Bayer to Present Data on PAH Drugs at ATS 2017

EMA Halts Use of Riociguat for PH Associated Idiopathic Interstitial Pneumonia

Riociguat Safe, Effective for Treating CTEPH Long-term

Bayer Terminates Phase II Study of Riociguat for PH-associated Idiopathic Interstitial Pneumonias

Riociguat Provides Hope for Difficult-to-Treat PAH Patients

All

Novel Pulmonary Hypertension Drug Proves Safe, Effective

Bayer’s Investigational Drug Shows Promise in PAH Treatment, Phase III Study Finds

All

Sorry, No Posts Found

Sorry, No Posts Found

Respiratory Therapy

Our Parent Company

Key Resources

Helpful Links